Sharecast - Indivior stated net revenue run rates from its Sublocade injection will hit $1.0bn by the end of 2025, while on a long-term view, it now expects to deliver Sublocade peak potential net revenues of more than $1.5bn - based on the expected positive market dynamics for buprenorphine medication-assisted treatment and on continued execution against its OHS strategy.
The FTSE 250-listed firm also said it expects to achieve a double-digit percentage net revenue compound annual growth rate over the medium term, driven primarily by Sublocade in the United States and growing net revenue contributions from its risperidone for extended-release injection.
"Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products Sublocade (Subutex PR) and Suboxone (buprenorphine/naloxone) Film. Additionally, the company assumes the U.S. market share of Suboxone Film, which it does not promote, will trend towards historical analogs for genericised medicines," said the group.
Indivior added that it expects to achieve "significant operating margin expansion" over the medium term, driven by an improving gross margin and focused management of operating expenses, and also said it had chosen the Nasdaq Composite for an additional share listing in the US.
As of 0855 GMT, Indivior shares were up 5.52% at 1,764.31p.
Reporting by Iain Gilbert at Sharecast.com
